Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 158

Sort by

Sort Order Select

Journal Articles

Abstract LB439: HP568, a highly potent and orally bioavailable ER PROTAC for breast cancer treatment, currently undergoing phase 1/2 clinical studies

Jing Li, Zhilin Tu, Luchan Deng, Zhipeng Quan, Wu Du, Xinghai Li

Cancer Res (2025) 85 (8_Supplement_2): LB439.

https://doi.org/10.1158/1538-7445.AM2025-LB439

Published: 25 April 2025

View articletitled, Abstract LB439: HP568, a highly potent and orally bioavailable ER PROTAC for breast cancer treatment, currently undergoing phase 1/2 clinical studies

Journal Articles

Abstract LB129: VTS105: A novel and potent BCMA/GPRC5D/CD3 trispecific T cell engager (TCE) for the treatment of hematologic malignancies and autoimmune diseases

Wei (Vivian) Wang, Bo Peng, Man Xu, Xuekun Zhang, Jing Li

Cancer Res (2025) 85 (8_Supplement_2): LB129.

https://doi.org/10.1158/1538-7445.AM2025-LB129

Published: 25 April 2025

View articletitled, Abstract LB129: VTS105: A novel and potent BCMA/GPRC5D/CD3 trispecific T cell engager (TCE) for the treatment of hematologic malignancies and autoimmune diseases

Journal Articles

Abstract 3101: Multitargeting of SHMT2 and purine biosynthesis is an effective antitumor treatment under hypoxia

Mathew Joseph Schneider, Carrie OConnor, Xun Bao, Md. Junayed Nayeen, Zhanjun Hou, Jing Li, Aleem Gangjee, Larry Matherly

Cancer Res (2025) 85 (8_Supplement_1): 3101.

https://doi.org/10.1158/1538-7445.AM2025-3101

Published: 21 April 2025

View articletitled, Abstract 3101: Multitargeting of SHMT2 and purine biosynthesis is an effective antitumor treatment under hypoxia

Journal Articles

Abstract 341: VBC108: a first-in-class CDH17/CLDN18.2 targeted bispecific antibody drug conjugate (ADC) to overcome tumor heterogeneity of gastrointestinal cancers (GC, PADC, CRC, etc.)

Wei (Vivian) Wang, Lingyu Guan, Man Xu, Qun Yin, Chen Dong, Jing Li

Cancer Res (2025) 85 (8_Supplement_1): 341.

https://doi.org/10.1158/1538-7445.AM2025-341

Published: 21 April 2025

View articletitled, Abstract 341: VBC108: a first-in-class CDH17/CLDN18.2 targeted bispecific antibody drug conjugate (ADC) to overcome tumor heterogeneity of gastrointestinal cancers (GC, PADC, CRC, etc.)

Journal Articles

Abstract 673: Protein Plus BCT: Ensuring reliable protein biomarker analysis in liquid biopsies by minimizing pre-analytical variations

Rachel M. Miller, Sama Mehta, Jing Li

Cancer Res (2025) 85 (8_Supplement_1): 673.

https://doi.org/10.1158/1538-7445.AM2025-673

Published: 21 April 2025

View articletitled, Abstract 673: Protein Plus BCT: Ensuring reliable protein biomarker analysis in liquid biopsies by minimizing pre-analytical variations

Journal Articles

Abstract 5885: Streck Urine Preserve provides cell-free DNA stabilization in whole urine for liquid biopsy

Jing Li, Sama Mehta

Cancer Res (2025) 85 (8_Supplement_1): 5885.

https://doi.org/10.1158/1538-7445.AM2025-5885

Published: 21 April 2025

View articletitled, Abstract 5885: Streck Urine Preserve provides cell-free DNA stabilization in whole urine for liquid biopsy

Journal Articles

Abstract 6689: Evaluating the influence of blood collection tubes and extraction kits on miRNA recovery in cancer biomarker research

Eunju Seong, Nicholas M. George, Jordan LaRue, Jing Li, Lisa Bartron

Cancer Res (2025) 85 (8_Supplement_1): 6689.

https://doi.org/10.1158/1538-7445.AM2025-6689

Published: 21 April 2025

View articletitled, Abstract 6689: Evaluating the influence of blood collection tubes and extraction kits on miRNA recovery in cancer biomarker research

Journal Articles

Abstract 279: Unraveling biological differences of high grade serous ovarian cancer subtypes by metabolomics

Zhanjun Hou, Madelyn Brzezinski, Carrie O’Connor, Xun Bao, Ayesha B. Alvero, Radhika Gogoi, Ramandeep Rattan, Gil Mor, Jing Li, Aleem Gangjee, Larry H. Matherly

Cancer Res (2025) 85 (8_Supplement_1): 279.

https://doi.org/10.1158/1538-7445.AM2025-279

Published: 21 April 2025

View articletitled, Abstract 279: Unraveling biological differences of high grade serous ovarian cancer subtypes by metabolomics

Journal Articles

Abstract 2226: Combined inhibition of MEK and HDACs improves the cytotoxicity of CD4 and CD8 T cells in NRAS;ASXL1-driven acute myeloid leukemia mice

Meher Gayatri Bolisetti, Jing Li, Bei Jia, Esra’a Keewan, Erik A. Ranheim, Kalyan V.G Nadiminti, Hong Zheng, Xiaona You, Jing Zhang

Cancer Res (2025) 85 (8_Supplement_1): 2226.

https://doi.org/10.1158/1538-7445.AM2025-2226

Published: 21 April 2025

View articletitled, Abstract 2226: Combined inhibition of MEK and HDACs improves the cytotoxicity of CD4 and CD8 T cells in NRAS;ASXL1-driven acute myeloid leukemia mice

Journal Articles

Abstract 2224: Impact of NT/NTR1 signaling on metabolic pathways and tumor-associated microbiomes in colorectal cancer

Haoming Wu, Yang Wang, Moumita Banerjee, Jinpeng Liu, Chi Wang, Dahe He, Thèrése Bocklage, Jing Li, B.Mark Evers

Cancer Res (2025) 85 (8_Supplement_1): 2224.

https://doi.org/10.1158/1538-7445.AM2025-2224

Published: 21 April 2025

View articletitled, Abstract 2224: Impact of NT/NTR1 signaling on metabolic pathways and tumor-associated microbiomes in colorectal cancer

Journal Articles

Abstract LB043: VBC101-F11: An innovative EGFR/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors

Wei (Vivian) Wang, Jing Li, Lin Ma, Man Xu, Qun Yin

Cancer Res (2024) 84 (7_Supplement): LB043.

https://doi.org/10.1158/1538-7445.AM2024-LB043

Published: 05 April 2024

View articletitled, Abstract LB043: VBC101-F11: An innovative EGFR/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors

Journal Articles

Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer

Linfeng Luo, Anlin Li, Wei Du, Maojian Chen, JIng Li, Yixin Zhou, Li Zhang, Shaodong Hong

Cancer Res (2024) 84 (7_Supplement): LB266.

https://doi.org/10.1158/1538-7445.AM2024-LB266

Published: 05 April 2024

View articletitled, Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer

Journal Articles

Abstract LB159: Discovery of HP560, a novel BET inhibitor for the treatment of myelofibrosis

Jing Li, Lei Fan, Hongwei Yuan, Yongxu Huo, Hua Yu, Fei Wang, Xinghai Li

Cancer Res (2024) 84 (7_Supplement): LB159.

https://doi.org/10.1158/1538-7445.AM2024-LB159

Published: 05 April 2024

View articletitled, Abstract LB159: Discovery of HP560, a novel BET inhibitor for the treatment of myelofibrosis

Journal Articles

Abstract CT289: A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)

Cancer Res (2024) 84 (7_Supplement): CT289.

https://doi.org/10.1158/1538-7445.AM2024-CT289

Published: 05 April 2024

View articletitled, Abstract CT289: A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)

Journal Articles

Abstract CT125: A phase 0/2 ‘trigger’ trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma

Nader Sanai, Yu-Wei Chang, Jun Jiang, Jennifer Molloy, Chelsea Pennington-Krygier, Jocelyn Harmon, Amy Hong, John Wanebo, William Kennedy, Michael Garcia, Igor Barani, Wonsuk Yoo, Artak Tovmasyan, An-Chi Tien, Jing Li, Shwetal Mehta

Cancer Res (2024) 84 (7_Supplement): CT125.

https://doi.org/10.1158/1538-7445.AM2024-CT125

Published: 05 April 2024

View articletitled, Abstract CT125: A phase 0/2 ‘trigger’ trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma

Journal Articles

Abstract LB179: Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer

Wu Du, Zhilin Tu, Dekun Qin, Haibo Li, Jingyi Duan, Shijuan Liu, Meng Zhang, Zhenyan Nie, Zhihui Yuan, Jing Li, Xinghai Li

Cancer Res (2024) 84 (7_Supplement): LB179.

https://doi.org/10.1158/1538-7445.AM2024-LB179

Published: 05 April 2024

View articletitled, Abstract LB179: Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer

Journal Articles

Abstract LB178: HP518, an oral AR-targeting PROTAC for the treatment of AR positive triple negative breast cancer with a novel mechanism of action

Jing Li, Hongwei Yuan, Kefan Chen, Yongxu Huo, Guoqing Liu, Wu Du, Xinghai Li

Cancer Res (2024) 84 (7_Supplement): LB178.

https://doi.org/10.1158/1538-7445.AM2024-LB178

Published: 05 April 2024

View articletitled, Abstract LB178: HP518, an oral AR-targeting PROTAC for the treatment of AR positive triple negative breast cancer with a novel mechanism of action

Journal Articles

Abstract LB177: Discovery of HC-4955, a novel AR-V7-targeting PROTAC for the treatment of mCRPC

Jing Li, Zhilin Tu, Wu Du, Xi Xiang, Zeyu Wen, Yang You, Lijuan Zhao, Yin Chen, Chengcheng Yang, Hongwei Yuan, Xinghai Li

Cancer Res (2024) 84 (7_Supplement): LB177.

https://doi.org/10.1158/1538-7445.AM2024-LB177

Published: 05 April 2024

View articletitled, Abstract LB177: Discovery of HC-4955, a novel AR-V7-targeting PROTAC for the treatment of mCRPC

Journal Articles

Abstract LB175: Discovery of HP567, a highly potent, brain-penetrating, and H1047R-selective PI3Kα inhibitor for the treatment of tumors bearing H1047R mutation

Jing Li, Lei Fan, Chengcheng Liu, Yao Luo, Xiaohui Chu, Hua Yu, Fei Wang, Xinghai Li

Cancer Res (2024) 84 (7_Supplement): LB175.

https://doi.org/10.1158/1538-7445.AM2024-LB175

Published: 05 April 2024

View articletitled, Abstract LB175: Discovery of HP567, a highly potent, brain-penetrating, and H1047R-selective PI3Kα inhibitor for the treatment of tumors bearing H1047R mutation

Journal Articles

Abstract LB448: VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond

Wei Wang, Jing Li, Lingyu Guan, Man Xu, Qun Yin

Cancer Res (2024) 84 (7_Supplement): LB448.

https://doi.org/10.1158/1538-7445.AM2024-LB448

Published: 05 April 2024

View articletitled, Abstract LB448: VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract LB439: HP568, a highly potent and orally bioavailable ER PROTAC for breast cancer treatment, currently undergoing phase 1/2 clinical studies

Abstract LB129: VTS105: A novel and potent BCMA/GPRC5D/CD3 trispecific T cell engager (TCE) for the treatment of hematologic malignancies and autoimmune diseases

Abstract 3101: Multitargeting of SHMT2 and purine biosynthesis is an effective antitumor treatment under hypoxia

Abstract 341: VBC108: a first-in-class CDH17/CLDN18.2 targeted bispecific antibody drug conjugate (ADC) to overcome tumor heterogeneity of gastrointestinal cancers (GC, PADC, CRC, etc.)

Abstract 673: Protein Plus BCT: Ensuring reliable protein biomarker analysis in liquid biopsies by minimizing pre-analytical variations

Abstract 5885: Streck Urine Preserve provides cell-free DNA stabilization in whole urine for liquid biopsy

Abstract 6689: Evaluating the influence of blood collection tubes and extraction kits on miRNA recovery in cancer biomarker research

Abstract 279: Unraveling biological differences of high grade serous ovarian cancer subtypes by metabolomics

Abstract 2226: Combined inhibition of MEK and HDACs improves the cytotoxicity of CD4 and CD8 T cells in NRAS;ASXL1-driven acute myeloid leukemia mice

Abstract 2224: Impact of NT/NTR1 signaling on metabolic pathways and tumor-associated microbiomes in colorectal cancer

Abstract LB043: VBC101-F11: An innovative EGFR/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors

Abstract LB266: AMG510-mediated inactivation of BCL-xL protein promotes Gasdermin-E-dependent pyroptosis in KRAS-G12C mutant non-small cell lung cancer

Abstract LB159: Discovery of HP560, a novel BET inhibitor for the treatment of myelofibrosis

Abstract CT289: A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)

Abstract CT125: A phase 0/2 ‘trigger’ trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma

Abstract LB179: Identification of the highly potent and orally available ER-targeting PROTAC degrader HP568 for the treatment of breast cancer

Abstract LB178: HP518, an oral AR-targeting PROTAC for the treatment of AR positive triple negative breast cancer with a novel mechanism of action

Abstract LB177: Discovery of HC-4955, a novel AR-V7-targeting PROTAC for the treatment of mCRPC

Abstract LB175: Discovery of HP567, a highly potent, brain-penetrating, and H1047R-selective PI3Kα inhibitor for the treatment of tumors bearing H1047R mutation

Abstract LB448: VBC103: An innovative Trop2/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only